Abstract
Prostaglandins (PGs) have been implicated as possible modulators of the immune response and various inflammatory processes1–4. Various cell components of the immune system are sources of PGs, and mitogen or antigen stimulation of human or murine lymphocytes leads to their enhanced release5–8. They are also released from various human and animal tumours9,10. Thus, as cells of the immune system are both sensitive to and sources of PGs, these factors may be important as physiological immune regulators. For example, PGs of the E series are capable of inhibiting many effector functions9–15. They have also been shown to inhibit the development of the humoral response16,17. Although they inhibit the proliferative response to mitogens18,19, little is known about their effects on the development of the cell-mediated immune response to antigens. The data summarized here implicate PGs, thromboxane A2 (TXA2) and prostacyclin (PGI2) in the regulation of cellular immune responses at the inductive phase. Some of these data have been reported in abstract form20.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bourne, H. R. et al. Science 184, 19–28 (1974).
Pelus, L. M. & Strasser, H. R. Life Sci. 20, 903–914 (1977).
Lewis, G. P. J. reticuloendothel. Soc. 22, 389–402 (1977).
Goodwin, J. S. & Webb, D. R. Clin. Immun. Immunopath. 15, 106–122 (1980).
Ferraris, V. A. & DeRubertis, F. R. J. clin. Invest. 54, 378–386 (1974).
Webb, D. R. & Osheroff, P. L. Proc. natn. Acad. Sci. U.S.A. 73, 1300–1304 (1976).
Youlten, L. J. F. & McCall, E. in Prostaglandins in Hematology (eds Silver, M. J., Smith, J. B. & Kocsis, J. J.) 87–90 (Spectrum, New York, 1977).
Humes, J. L. et al. Nature 269, 149–151 (1977).
Jaffe, B. M. Prostaglandins 6, 453–461 (1974).
Easty, G. C. & Easty, D. M. Cancer Treat. Rev. 3, 217–225 (1976).
Henney, C. S., Bourne, H. R. & Lichtenstein, L. M. J. Immun. 108, 1526–1534 (1972).
Strom, T. B. et al. J. exp. Med. 138, 381–383 (1973).
Gorden, D., Bray, M. A. & Morley, J. Nature 262, 401–402 (1976).
Schultz, R. M., Pavlidis, N. A., Stylos, W. A. & Chirigos, M. A. Science 202, 320–321 (1978).
Plaut, M. J. Immun. 123, 692–701 (1979).
Plescia, O. J., Smith, A. H. & Grinwich, K. Proc. natn. Acad. Sci. U.S.A. 72, 1848–1851 (1975).
Webb, D. R. & Nowoweijski, I. Cell Immun. 33, 1–10 (1977).
Goodwin, J. S., Bankhurst, A. D. & Messner, R. P. J. exp. Med. 146, 1719–1734 (1977).
Webb, D. R. & Nowowiejski, I. Cell Immun. 41, 72–85 (1978).
Leung, K. H. & Mihich, E. 63rd A. Meet. Fedn Am. Soc. exp. Biol., Dallas, Texas (1–10 April, 1979); 1st Int. Conf. Immunopharmac., Brighton (29 July–1 August, 1980).
Goodwin, J. S., Messner, R. P. & Peake, G. T. J. clin. Invest. 62, 753–760 (1978).
Samuelsson, B. et al. A. Rev. Biochem. 47, 997–1029 (1978).
Vane, J. R. Adv. Prostaglandin Thromboxane Res. 4, 27–44 (1978).
Brune, K., Glatt, M., Kalin, H. & Peskar, B. A. Nature 274, 261–263 (1978).
Morley, M. A., Bray, M. A., Jones, R. W., Nuteven, D. H. & Van Doryn, D. A. Prostaglandins 17, 730–746 (1979).
Gryglewski, R. J., Bunting, S., Moncada, S., Flower, R. J. & Vane, J. R. Prostaglandins 12, 685–713 (1976).
Moncada, S. et al. Prostaglandins 13, 611–618 (1977).
Parker, C. W., Stevenson, W. F., Huler, M. G. & Kelly, J. P. J. Immun. 122, 1572 (1979).
Needleman, P. et al. Prostaglandins 14, 897–907 (1977).
Cerottini, J.-C., Engers, H. D., MacDonald, H. R. & Brunner, K. T. J. exp. Med. 140, 703–717 (1974).
Mawas, C., Carey, T. & Mihich, E. Cell Immun. 6, 243–260 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leung, K., Mihich, E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 288, 597–600 (1980). https://doi.org/10.1038/288597a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/288597a0
This article is cited by
-
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia
Scientific Reports (2020)
-
Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice
Cancer Immunology Immunotherapy (1995)
-
Preclinical studies of antitumor prostaglandins by using human ovarian cancer cells
Cancer and Metastasis Reviews (1994)
-
Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis
Diseases of the Colon & Rectum (1994)
-
Acetylsalicylic acid and misoprostol combination in adjuvant arthritis of rats
Inflammation (1993)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
